Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have been given an average rating of “Moderate Buy” by the nine ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $18.00.

Several research analysts have recently commented on TVRD shares. BTIG Research lowered their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a research note on Wednesday, July 8th. UBS Group upgraded shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, July 8th. HC Wainwright assumed coverage on shares of Tvardi Therapeutics in a research report on Monday, June 8th. They issued a “buy” rating and a $9.00 price target for the company. Finally, Wall Street Zen upgraded shares of Tvardi Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd.

Tvardi Therapeutics Trading Up 1.1%

TVRD stock opened at $1.82 on Monday. The company has a market capitalization of $24.28 million, a PE ratio of -0.65 and a beta of 0.39. Tvardi Therapeutics has a 12-month low of $1.50 and a 12-month high of $43.65. The business’s fifty day moving average price is $2.32 and its 200 day moving average price is $3.04.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Research analysts predict that Tvardi Therapeutics will post -2.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Susquehanna International Group LLP acquired a new stake in Tvardi Therapeutics in the second quarter valued at approximately $63,000. BlackRock Inc. acquired a new position in Tvardi Therapeutics during the 2nd quarter worth approximately $181,000. GSA Capital Partners LLP acquired a new position in Tvardi Therapeutics during the 2nd quarter worth approximately $34,000. XTX Topco Ltd purchased a new stake in shares of Tvardi Therapeutics in the 4th quarter valued at approximately $55,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Tvardi Therapeutics in the 4th quarter valued at approximately $90,000. 44.66% of the stock is owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.